Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Assembly Biosciences Inc (NASDAQ:ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core…
Biogen Reveals $900M Settlement In Whistleblower’s MS Drug Kickbacks Lawsuit Days Before Trial
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlemen
Chardan Initiates Coverage On These ‘Intriguing Small-Cap Stories”
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with…
Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ:PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now…
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Soligenix Inc (NASDAQ:SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL)…
Aytu BioPharma Commences Late-Stage Genetic Disorder Study
Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS).
AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study
AIM ImmunoTech Inc (NYSE:AIM) reported follow-on data from its published single-center named patient program. For the study, patients with locally advanced…
Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful
Soleno Therapeutics Inc (NASDAQ:SLNO) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline)…
Rhythm Shares Shoot Higher Following Pre-marketing Authorization From French Regulatory For Multisystem Disorder Candidate
The French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (early access authorization), for Rhythm Pharmaceuticals’ (NASDAQ: RYTM) lead candidate IMCIVREE (setmelanotide) in patients with genetically-conf